Aardvark Therapeutics to Present at Upcoming Investor Conferences in December

Core Insights - Aardvark Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule therapeutics aimed at treating metabolic diseases, particularly through the activation of innate homeostatic pathways [2] Company Overview - Aardvark is developing novel therapeutics designed to suppress hunger, specifically targeting conditions like Prader-Willi Syndrome (PWS) and other metabolic diseases [2] - The lead compound, ARD-101, is currently in Phase 3 clinical development for hyperphagia associated with PWS and is also being studied for hypothalamic obesity [2] - Aardvark is also working on ARD-201, a fixed-dose combination of ARD-101 with a DPP-4 inhibitor, to address limitations of existing GLP-1 therapies for obesity and related conditions [2] Upcoming Events - Aardvark will present at the Piper Sandler 37th Annual Healthcare Conference in New York on December 3 at 8:00 a.m. ET [4] - The company will also present at the Evercore ISI 8th Annual Healthcare Conference in Miami on December 4 at 11:15 a.m. ET [4] - Live webcasts of these presentations will be available on the company's website, with archived recordings accessible for approximately one month [1]